Figure 1
Experimental design of ZD6126 therapy for gastric cancer growing in an orthotopic site. TMK-1 human gastric cancer cells (106) were injected into the gastric walls of nude mice. Mice were randomised to one of three groups: control, ZD6126 1 day week−1, or ZD6126 5 days week−1. Treatment with ZD6126 (100 mg kg−1) or control began on day 14 by i.p. injection. On day 38, all mice were euthanised.
